Abstract: The present invention relates to the treatment and prevention of malaria infection. In particular, the present invention provides novel noninfectious, whole organism vaccines for malaria, which vaccines comprise a Plasmodium axenic liver stage. The invention also provides methods to treat and prevent malaria by administering such Plasmodium axenic liver stage vaccines, as well as methods to generate Plasmodium axenic liver stages.

Abstract: The present invention relates to the treatment and prevention of malaria infection. In particular, the present invention provides novel noninfectious, whole organism vaccines for malaria, which vaccines comprise a Plasmodium axenic liver stage. The invention also provides methods to treat and prevent malaria by administering such Plasmodium axenic liver stage vaccines, as well as methods to generate Plasmodium axenic liver stages.

Abstract: Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.

Abstract: There is provided peptide and mimetic inhibitors for the binding of a circumsporozoite polypeptide to receptors of hepatocytes from malaria-susceptible mammals. Also contemplated is a method of inhibiting the binding of a malaria sporozoites to hepatocytes susceptible to sporozoite invasion. A peptide of Region II+ of the circumsporozoite protein is also provided, as is a method of targeting the delivery of substances to hepatocytes.

Abstract: This application relates to nucleic acids encoding decay accelerating factor (hereinafter abbreviated as DAF), as well as vectors and cells which comprise such nucleic acids. Additionally, nucleic acids which encode variants of DAF, such as insertion, deletion or substitution variants, are described. This application also relates to the preparation of DAF in recombinant cell culture. In particular, it is concerned with the large scale manufacture of DAF suitable for pharmaceutical or diagnostic use.

Abstract: A synthetic peptide comprising an amino acid sequence including the sequence Asp-Arg-Ala-X-Gly-Gln-Pro-Ala-Gly wherein X is selected from the group consisting of Asp and Ala, said peptide being capable of eliciting formation of antibodies recognizing the circumsporozoite protein of Plasmodium vivax sporozoites.

Abstract: Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.

Abstract: The present invention provides an immunoassay of general applicability. The assay detects an antigen by its inhibition of the reaction between the combining site of two antibodies. One of the antibodies binds antigen, and the second antibody binds to the combining site or idiotype of the first antibody. It is preferable that both the antibody that binds the antigen and the anti-idiotypic antibody are monoclonal antibodies. The assay provides a method for measuring concentrations of single epitopes without requiring purified antigen, and it is particularly useful for measuring the quantity of any nonpurified antigen present in low concentration in a mixture of antigens. The use of monoclonal antibodies as reagents is advantageous in providing an essentially unlimited supply of highly specific and standardized reagents, without the batch-to-batch variation encountered when using conventional polyclonal antibodies.

Abstract: This invention relates to a synthetic polypeptide (preferably produced by recombinant DNA techniques) comprising an amino acid sequence incorporating (a) a portion of the P.vivax circumsporozoite (CS) protein including the region of the repeat immunodominant epitope of said protein and (b) another portion of such protein which is conserved among the different material species; and to a method for purifying such a polypeptide.

Abstract: Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.

Abstract: Described is an immunogenic polypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast.

Abstract: A method for inhibiting the development or limiting the extent of malarial parasitemia in mammals comprising administering an amount of gamma-interferon sufficient to inhibit parasitemia, said parasitemia being incident to invasion of said mammal by sporozoites of a member of the genus Plasmodium. The administration of gamma-interferon takes place no later than the end of the prepatency period of said mammal (or of the dormant phase of the parasite as the case may be).

Abstract: Described is an immunogenic polypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast.

Abstract: The present invention provides antisera and monoclonal antibodies directed against the sporozoite stage of the malaria parasite capable of providing protection against infection in both animals and humans. The invention further provides a purified antigen derived from sporozoites of the malaria parasite, the antigen being suitable for use as a vaccine against malarial infections in both animals and humans. The invention further provides means for preparing said antigen and a vaccine comprising said antigen.